An economic evaluation of universal pertussis vaccination in Italy

Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age

“…In accordance with general recommendations for anti-infective prevention strategies, the Italian Ministry of Health implemented only paediatric vaccinations that were either cost saving or costeffective. [53][54][55][56] Consequently, influenza immunization is currently recommended only in older-age and high-risk individuals. Therefore, less than 5% of Italian children below 60 months of age actually receive influenza vaccination.…”

Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

“…However, comparisons with other programmes that are currently funded are possible and may be legitimate references for public health decision makers. Other universal vaccinations of infants currently implemented in Italy are either cost-saving, such as pertussis and hepatitis B vaccinations [54,55], or more cost-effective, such as the vaccination against HiB [56]. Nonetheless, universal vaccination of infants with the pneumococcal conjugate vaccine would have a very low cost per averted case in Lazio, i.e.…”

The distribution over time of costs and social net benefits for pertussis immunization programs

“…A case of uncomplicated pertussis without hospitalisation was estimated at two physician visits and a 10-day course of erythromycin at e7.50. Treatment cost of pneumonia, seizures and encephalopathy was calculated with a mean number of 10, 6 and 15 hospital days respectively (Beutels et al 1999) with two general practitioner consultations for each of these complications.…”